147 related articles for article (PubMed ID: 28812471)
1. Effectiveness and tolerability of parenteral testosterone undecanoate: a post-marketing surveillance study.
Wolf J; Keipert D; Motazedi H; Ernst M; Nettleship J; Gooren L
Aging Male; 2017 Dec; 20(4):225-234. PubMed ID: 28812471
[TBL] [Abstract][Full Text] [Related]
2. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M
J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study.
Moon DG; Park MG; Lee SW; Park K; Park JK; Kim SW; Park NC; Ahn TY; Paick JS; Seo JT; Yang DY; Lee JY; Kim JJ
J Sex Med; 2010 Jun; 7(6):2253-2260. PubMed ID: 20345732
[TBL] [Abstract][Full Text] [Related]
4. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P; Saghir A;
Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040
[TBL] [Abstract][Full Text] [Related]
5. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism.
Minnemann T; Schubert M; Freude S; Hübler D; Gouni-Berthold I; Schumann C; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
J Endocrinol Invest; 2008 Aug; 31(8):718-23. PubMed ID: 18852533
[TBL] [Abstract][Full Text] [Related]
6. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
Permpongkosol S; Khupulsup K; Leelaphiwat S; Pavavattananusorn S; Thongpradit S; Petchthong T
J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
[TBL] [Abstract][Full Text] [Related]
7. The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism.
Giagulli VA; Triggiani V; Carbone MD; Corona G; Tafaro E; Licchelli B; Guastamacchia E
J Sex Med; 2011 Dec; 8(12):3471-8. PubMed ID: 21995803
[TBL] [Abstract][Full Text] [Related]
8. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
von Eckardstein S; Nieschlag E
J Androl; 2002; 23(3):419-25. PubMed ID: 12002444
[TBL] [Abstract][Full Text] [Related]
9. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints.
Permpongkosol S; Tantirangsee N; Ratana-olarn K
J Sex Med; 2010 Nov; 7(11):3765-74. PubMed ID: 20807330
[TBL] [Abstract][Full Text] [Related]
10. Testosterone undecanoate in the treatment of male hypogonadism.
Edelstein D; Basaria S
Expert Opin Pharmacother; 2010 Aug; 11(12):2095-106. PubMed ID: 20642374
[TBL] [Abstract][Full Text] [Related]
11. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice.
Conaglen HM; Paul RG; Yarndley T; Kamp J; Elston MS; Conaglen JV
J Sex Med; 2014 Feb; 11(2):574-82. PubMed ID: 24279472
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men.
Zitzmann M; Nieschlag E
J Clin Endocrinol Metab; 2007 Oct; 92(10):3844-53. PubMed ID: 17635942
[TBL] [Abstract][Full Text] [Related]
13. Injectable testosterone undecanoate for the treatment of hypogonadism.
Corona G; Maseroli E; Maggi M
Expert Opin Pharmacother; 2014 Sep; 15(13):1903-26. PubMed ID: 25080279
[TBL] [Abstract][Full Text] [Related]
14. Testosterone depot injection in male hypogonadism: a critical appraisal.
Yassin AA; Haffejee M
Clin Interv Aging; 2007; 2(4):577-90. PubMed ID: 18225458
[TBL] [Abstract][Full Text] [Related]
15. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
Schubert M; Minnemann T; Hübler D; Rouskova D; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
[TBL] [Abstract][Full Text] [Related]
16. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men.
Nieschlag E; Büchter D; Von Eckardstein S; Abshagen K; Simoni M; Behre HM
Clin Endocrinol (Oxf); 1999 Dec; 51(6):757-63. PubMed ID: 10619981
[TBL] [Abstract][Full Text] [Related]
17. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study.
Aversa A; Bruzziches R; Francomano D; Rosano G; Isidori AM; Lenzi A; Spera G
J Sex Med; 2010 Oct; 7(10):3495-503. PubMed ID: 20646185
[TBL] [Abstract][Full Text] [Related]
18. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome.
Francomano D; Ilacqua A; Bruzziches R; Lenzi A; Aversa A
Urology; 2014 Jan; 83(1):167-73. PubMed ID: 24139347
[TBL] [Abstract][Full Text] [Related]
19. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism.
Meuleman EJ; Legros JJ; Bouloux PM; Johnson-Levonas AO; Kaspers MJ; Elbers JM; Geurts TB; Meehan AG;
Aging Male; 2015; 18(3):157-63. PubMed ID: 26030346
[TBL] [Abstract][Full Text] [Related]
20. Unexpectedly prolonged washout period of exogenous testosterone after discontinuation of intramuscular testosterone undecanoate depot injection (Nebido(®) or Reandron(®) ) in men with congenital hypogonadotrophic hypogonadism.
Gan EH; Bouloux PM; Quinton R
Clin Endocrinol (Oxf); 2016 Jun; 84(6):947-50. PubMed ID: 26732131
[No Abstract] [Full Text] [Related]
[Next] [New Search]
